Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Refractory Malignant Ascites
NCT03020979Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Jan 2017
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib in malignant ascites, sponsored by First Affiliated Hospital of Bengbu Medical University. Started Jan 2017; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
malignant ascites
Beyond the preview
Go deeper on NCT03020979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03020979.